WO2026002174 - CAMPTOTHECIN DERIVATIVE AND PREPARATION THEREOF
National phase entry is expected:
Publication Number
WO/2026/002174
Publication Date
02.01.2026
International Application No.
PCT/CN2025/104151
International Filing Date
27.06.2025
Title **
[English]
CAMPTOTHECIN DERIVATIVE AND PREPARATION THEREOF
[French]
DÉRIVÉ DE CAMPTOTHÉCINE ET SA PRÉPARATION
[Chinese]
一种喜树碱衍生物及其制备
Applicants **
LUNAN NEW TIME BIOTECHNICAL CO.. LTD.
Inventors
ZHAO, Lili
LIU, Zhong
ZHANG, Guimin
LAN, Tianlong
ZHAO, Xuliang
Priority Data
202410844871.5
27.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1897 | |
| EPO | Filing, Examination, Granting | 12243 | |
| Japan | Filing, Examination, Granting | 2161 | |
| South Korea | Filing, Examination, Granting | 2121 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,162
Contact Us
Abstract[English]
Provided in the present invention are a camptothecin derivative and an antibody-drug conjugate thereof. The compound has a high activity, low toxicity and good affinity, and achieves a direct targeted killing effect on tumor cells with the antibody-drug conjugate. The antibody-drug conjugate containing the antibody exhibits a significant cell killing effect, and has a high tumor inhibition rate.[French]
La présente invention concerne un dérivé de camptothécine et un conjugué anticorps-médicament associé. Le composé présente une activité élevée, une faible toxicité et une bonne affinité, et permet d'obtenir un effet destructeur ciblé direct sur des cellules tumorales avec le conjugué anticorps-médicament. Le conjugué anticorps-médicament contenant l'anticorps présente un effet de destruction cellulaire significatif, et a un taux d'inhibition tumorale élevé.[Chinese]
本发明提供了一种喜树碱衍生物及其抗体-药物偶联物；该化合物活性高且毒性小，亲和力好，与抗体药物偶联物实现了对肿瘤细胞的直接靶向杀伤作用，包含该抗体的抗体药物偶联物细胞杀伤效果显著，并具有很强的肿瘤抑制率。